← Leaderboards
Jean Matheson
Beth Israel Deaconess Medical Center
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Thomas Emery Scammell$14,139,696
- Susan L Greenspan$27,746,173
- Patrick Michael Fuller$14,560,936
- Michael B Atkins$4,622,469
- K Lea Sewell$387,832
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectDrug Screening /EvaluationEnzyme Linked Immunosorbent AssayHuman Therapy EvaluationPositive Pressure BreathingSleepCentral Nervous System StimulantsSleep ApneaComplement Pathway
Grant awards (10)
INFLUENCE OF SLEEP ON THE ACTIVATION OF COMPLEMENT IN NORMAL SUBJECTS$0
M01 · FY2002 · RR
PROVIGIL (MODAFINIL) TREATMENT IN SLEEP APNEA$0
M01 · FY2002 · RR
INFLUENCE OF SLEEP ON THE ACTIVATION OF COMPLEMENT IN NORMAL SUBJECTS$0
M01 · FY2001 · RR
PROVIGIL (MODAFINIL) TREATMENT IN SLEEP APNEA$0
M01 · FY2001 · RR
PROVIGIL (MODAFINIL) TREATMENT IN SLEEP APNEA$0
M01 · FY2000 · RR
INFLUENCE OF SLEEP ON THE ACTIVATION OF COMPLEMENT IN NORMAL SUBJECTS$0
M01 · FY2000 · RR
PROVIGIL (MODAFINIL) TREATMENT IN SLEEP APNEA$0
M01 · FY2000 · RR
INFLUENCE OF SLEEP ON THE ACTIVATION OF COMPLEMENT IN NORMAL SUBJECTS$0
M01 · FY2000 · RR
INFLUENCE OF SLEEP ON THE ACTIVATION OF COMPLEMENT IN NORMAL SUBJECTS$0
M01 · FY2000 · RR
PROVIGIL (MODAFINIL) TREATMENT IN SLEEP APNEA$0
M01 · FY2000 · RR